Clinical trials
Cellulitis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 8 |
| 2008 | 9 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
| Terminated | 5 |
| No longer available | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 4 |
| 59th Medical Wing | 3 |
| Brigham and Women's Hospital | 3 |
| Durata Therapeutics Inc., an affiliate of Allergan plc | 3 |
| Forest Laboratories | 3 |
| Melinta Therapeutics, Inc. | 3 |
| Ohio State University | 3 |
| Arpida AG | 2 |
| Children's Hospital of Philadelphia | 2 |
| Cumberland Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cellulitis | 74 |
| Abscess | 27 |
| Wound Infection | 13 |
| Bacterial Infections | 9 |
| Infections | 8 |
| Soft Tissue Infections | 6 |
| Staphylococcal Infections | 6 |
| Pneumonia | 5 |
| Skin Diseases, Bacterial | 5 |
| Surgical Wound Infection | 5 |
Trials
Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.